165 related articles for article (PubMed ID: 9671748)
1. Tumors of DNA mismatch repair-deficient hosts exhibit dramatic increases in genomic instability.
Baross-Francis A; Andrew SE; Penney JE; Jirik FR
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8739-43. PubMed ID: 9671748
[TBL] [Abstract][Full Text] [Related]
2. Tumors arising in DNA mismatch repair-deficient mice show a wide variation in mutation frequency as assessed by a transgenic reporter gene.
Baross-Francis A; Milhausen MK; Andrew SE; Jevon G; Jirik FR
Carcinogenesis; 2000 Jun; 21(6):1259-62. PubMed ID: 10837019
[TBL] [Abstract][Full Text] [Related]
3. Thymic lymphomas arising in Msh2 deficient mice display a large increase in mutation frequency and an altered mutational spectrum.
Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
Mutat Res; 2002 Mar; 500(1-2):67-74. PubMed ID: 11890935
[TBL] [Abstract][Full Text] [Related]
4. Candidate mutator genes in mismatch repair-deficient thymic lymphomas: no evidence of mutations in the DNA polymerase delta gene.
Campbell MR; Thang TY; Jirik FR; Andrew SE
Carcinogenesis; 2000 Dec; 21(12):2281-5. PubMed ID: 11133819
[TBL] [Abstract][Full Text] [Related]
5. Msh2 DNA mismatch repair gene deficiency and the food-borne mutagen 2-amino-1-methy1-6-phenolimidazo [4,5-b] pyridine (PhIP) synergistically affect mutagenesis in mouse colon.
Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
Oncogene; 2001 Sep; 20(42):6066-72. PubMed ID: 11593414
[TBL] [Abstract][Full Text] [Related]
6. Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent.
Andrew SE; McKinnon M; Cheng BS; Francis A; Penney J; Reitmair AH; Mak TW; Jirik FR
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):1126-30. PubMed ID: 9448296
[TBL] [Abstract][Full Text] [Related]
7. Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice.
Andrew SE; Reitmair AH; Fox J; Hsiao L; Francis A; McKinnon M; Mak TW; Jirik FR
Oncogene; 1997 Jul; 15(2):123-9. PubMed ID: 9244348
[TBL] [Abstract][Full Text] [Related]
8. Elevated mutant frequencies and predominance of G:C to A:T transition mutations in Msh6(-/-) small intestinal epithelium.
Mark SC; Sandercock LE; Luchman HA; Baross A; Edelmann W; Jirik FR
Oncogene; 2002 Oct; 21(46):7126-30. PubMed ID: 12370835
[TBL] [Abstract][Full Text] [Related]
9. Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts.
Andrew SE; Xu XS; Baross-Francis A; Narayanan L; Milhausen K; Liskay RM; Jirik FR; Glazer PM
Carcinogenesis; 2000 Jul; 21(7):1291-5. PubMed ID: 10874005
[TBL] [Abstract][Full Text] [Related]
10. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis.
Qin X; Zhou H; Liu L; Gerson SL
Carcinogenesis; 1999 Sep; 20(9):1667-73. PubMed ID: 10469609
[TBL] [Abstract][Full Text] [Related]
11. Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type.
Wang Q; Montmain G; Ruano E; Upadhyaya M; Dudley S; Liskay RM; Thibodeau SN; Puisieux A
Hum Genet; 2003 Feb; 112(2):117-23. PubMed ID: 12522551
[TBL] [Abstract][Full Text] [Related]
12. Methylation of CpG dinucleotides in the lacI gene of the Big Blue transgenic mouse.
You YH; Halangoda A; Buettner V; Hill K; Sommer S; Pfeifer G
Mutat Res; 1998 Dec; 420(1-3):55-65. PubMed ID: 9838042
[TBL] [Abstract][Full Text] [Related]
13. Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bcl-2 rearrangements.
Indraccolo S; Minuzzo S; Nicoletti L; Cretella E; Simon M; Papakonstantinou G; Hehlmann R; Mion M; Bertorelle R; Roganovic J; Chieco-Bianchi L
Blood; 1999 Oct; 94(7):2424-32. PubMed ID: 10498615
[TBL] [Abstract][Full Text] [Related]
14. MSH2-deficient murine lymphomas harbor insertion/deletion mutations in the transforming growth factor beta receptor type 2 gene and display low not high frequency microsatellite instability.
Lowsky R; Magliocco A; Ichinohasama R; Reitmair A; Scott S; Henry M; Kadin ME; DeCoteau JF
Blood; 2000 Mar; 95(5):1767-72. PubMed ID: 10688836
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer.
de Wind N; Dekker M; Berns A; Radman M; te Riele H
Cell; 1995 Jul; 82(2):321-30. PubMed ID: 7628020
[TBL] [Abstract][Full Text] [Related]
16. A lack of DNA mismatch repair on an athymic murine background predisposes to hematologic malignancy.
Campbell MR; Nation PN; Andrew SE
Cancer Res; 2005 Apr; 65(7):2626-35. PubMed ID: 15805259
[TBL] [Abstract][Full Text] [Related]
17. The mutational specificity of 1-nitroso-6-nitropyrene in the lacI gene of Escherichia coli strains deficient in nucleotide excision repair.
Lambert IB; Carroll C; Laycock N; Duval L; Whiteway J; Lawford I; Turner G; Booth R; Douville S; Nokhbeh MR
Mutagenesis; 1998 Jan; 13(1):9-18. PubMed ID: 9491388
[TBL] [Abstract][Full Text] [Related]
18. Increased mutation frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone p53/Big Blue double transgenic mice.
Buettner VL; Hill KA; Nishino H; Schaid DJ; Frisk CS; Sommer SS
Oncogene; 1996 Dec; 13(11):2407-13. PubMed ID: 8957082
[TBL] [Abstract][Full Text] [Related]
19. Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6.
Hegan DC; Narayanan L; Jirik FR; Edelmann W; Liskay RM; Glazer PM
Carcinogenesis; 2006 Dec; 27(12):2402-8. PubMed ID: 16728433
[TBL] [Abstract][Full Text] [Related]
20. A novel lacI transgenic mutation-detection system and its application to establish baseline mutation frequencies in the scid mouse.
Andrew SE; Pownall S; Fox J; Hsiao L; Hambleton J; Penney JE; Kohler SW; Jirik FR
Mutat Res; 1996 Oct; 357(1-2):57-66. PubMed ID: 8876680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
